Rate My Professor Robert Clancy

Robert Clancy, Emeritus Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy within the College of Health, Medicine and Wellbeing, is a pioneering clinical immunologist with a distinguished career in pathology. He earned his BSc (Med) (Hons) and MBBS (Hons) from the University of Sydney, a PhD from Monash University, and was awarded a Doctor of Science (DSc) by the University of Newcastle for his studies of infection and immune responses at mucosal surfaces. A Fellow of the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists of Australia (FRCPA), Professor Clancy served as the first Clinical Immunologist at Royal Prince Alfred Hospital in Sydney before becoming the Foundation Professor of Pathology at the University of Newcastle's Faculty of Medicine, a role he held until his retirement in 2016. He continues as a senior clinical immunologist with ongoing involvement in the management of immune disorders.

Professor Clancy possesses an international reputation in mucosal immunology, with research specializations encompassing infections of the airways and gut, the body's processing of infections, and vaccine development to prevent or modify infectious diseases. His pioneering investigations into the gut-lung immune axis demonstrated that immune stimulation in the gut generates migrating cells that confer protection against respiratory tract infections. In 1985, he led the team that developed the Broncostat vaccine at the University of Newcastle, commercialized in 1989, which reduces acute bronchitis exacerbations by up to 90 percent in chronic obstructive pulmonary disease patients. Key publications include the review 'Towards a vaccine for chronic obstructive pulmonary disease' (Internal Medicine Journal, 2012) and contributions to over 200 research works on host-microbe interactions and mucosal immunity. Awarded the Member of the Order of Australia (AM) in 2005 for service to immunology and cartography, his work has profoundly influenced therapeutic strategies for respiratory infections.